Fortress Biotech
FBIO
65 hedge funds and large institutions have $13.7M invested in Fortress Biotech in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 10 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
0.08% more ownership
Funds ownership: 0.96% → 1.04% (+0.08%)
0% more funds holding
Funds holding: 65 → 65 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
40% less capital invested
Capital invested by funds: $22.9M → $13.7M (-$9.21M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $31K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$575K |
| 2 |
Renaissance Technologies
New York
|
+$557K |
| 3 |
OPPM
Opus Point Partners Management
New York
|
+$499K |
| 4 |
JP Morgan Chase
New York
|
+$311K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$603K |
| 2 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$369K |
| 3 |
Morgan Stanley
New York
|
-$111K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$84.9K |
| 5 |
BMCM
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
|
-$78K |
FBIO Hedge Fund Activity: Q3 2018 in Review
65 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q3 2018, worth a combined $13.7M — down 40% from $22.9M a quarter earlier.
Fund positioning in FBIO was balanced in Q3 2018: 10 funds opened new positions, 10 closed out, 21 added to existing stakes and 12 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $575K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $603K sold.
- 65 institutional investors held Fortress Biotech (FBIO) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $13.7M of Fortress Biotech stock for Q3 2018, down 40% quarter-over-quarter.
- 10 funds opened new Fortress Biotech positions in Q3 2018 and 10 closed out, a net change of 0 holders.
- The largest Fortress Biotech buyer in Q3 2018 was Deutsche Bank, an estimated $575K added.
- The largest Fortress Biotech seller in Q3 2018 was Highbridge Capital Management, an estimated $603K sold.
Based on aggregated 13F filings for Q3 2018.